FIELD: medicine, pharmaceutics.
SUBSTANCE: there are offered a dalargin-containing intranasal composition suspended or dissolved in a liquid propellant, containing stabilising and suspending agents and/or cosolvents, and its application for treating the diseases (particularly, gastric ulcer, duodenal ulcer, pancreatitis, pancreatonecrosis).
EFFECT: it is shown that the intranasal composition provides good absorbability; due to optimum viscosity the composition is distributed over a surface of a nasal mucosa and kept there for a long time, as well as higher bioavailability and a prolonged therapeutic effect of the declared agent in comparison with traditional dalargin compositions.
6 cl, 1 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
MEDICATION FOR FUNCTIONAL GASTROINTESTINAL DISORDERS | 2020 |
|
RU2744125C1 |
METHOD FOR TREATING GASTRODUODENAL PEPTIC ULCERS | 1999 |
|
RU2159125C1 |
USE OF DALARGIN FOR PRODUCTION OF DRUG PREPARATIONS FOR PREVENTING PNEUMONIA | 2020 |
|
RU2728938C1 |
METHOD FOR TREATING PEPTIC ULCERS | 1994 |
|
RU2098098C1 |
METHOD OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME BY DALARGIN AND A PULMONARY SURFACTANT | 2020 |
|
RU2728821C1 |
METHOD OF TREATING HYPOTHYROIDISM WITH DALARGIN | 2023 |
|
RU2814749C1 |
METHOD OF TREATING DIABETES MELLITUS IN COMPLEX WITH DALARGIN | 2023 |
|
RU2816021C1 |
ORAL PHARMACEUTICAL COMPOSITION FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES | 2010 |
|
RU2445965C2 |
INJECTION DALARGIN SOLUTION | 2003 |
|
RU2241488C1 |
AGENT FOR THERAPY OF WOUND AND BURN SKIN LESIONS | 2018 |
|
RU2687485C1 |
Authors
Dates
2011-12-20—Published
2010-07-06—Filed